Contributors
DM drafted the manuscript. AM conceived, and coordinated subsequent
edits and revisions. MS and TR participated in drafting the manuscript
and its finalization. All authors have read and approved the final
manuscript.
Table 1 Disproportionality analysis (reporting odds ratio
[ROR] and its 95% confidence interval [CI]) of selected cancers
and total neoplasms for omalizumab in VigiBase for the period between
2000 and 2020.